Navigation Links
Jade Therapeutics Elects Veteran Life Science Entrepreneur Dinesh Patel, Ph.D., to its Board of Directors
Date:11/13/2013

SALT LAKE CITY, Nov. 13, 2013 /PRNewswire/ -- Jade Therapeutics, Inc. announced today the election of veteran life science entrepreneur and venture capitalist Dinesh Patel, Ph.D., to the Company's Board of Directors, replacing SCI Institute Associate Director Dr. Greg Jones.

(Logo: http://photos.prnewswire.com/prnh/20131113/PH15704LOGO

Dr. Patel co-founded the venture capital firm vSpring Capital (now Signal Peak Ventures) in 2000 and is currently Partner Emeritus. From 1985-1999, he served as Co-Founder, Chairman, and President & CEO of TheraTech, Inc., a biotechnology company that he took public and eventually sold to Watson Pharmaceuticals for $350 million. He was also Founder, Chairman, President & CEO of Ashni Naturaceuticals, and he co-founded and was Chairman of the biotechnology company Salus Therapeutics. In addition, he served on the Board of online medical records provider MediConnect Global, Inc., which was acquired in 2012 by Verisk Analytics for $350 million.

Dr. Patel is currently Chairman of USTAR's Governing Authority board and has won numerous awards including the 2006 Utah Technology Council Hall of Fame Inductee, the U.S. Small Business Administration's Business Achiever Award, Entrepreneur of the Year (Mountain West Venture Group), and most recently BioUtah's flagship award, the Willem J. Kolff Lifetime Achievement Award.

"We are grateful to Greg for his important assistance to Jade from our company's earliest days, and we are indeed honored that Dinesh is now joining our Board," said Jade CEO Arthur Klausner.  "Dinesh's wealth of experience in both drug delivery and ophthalmology represents a terrific fit for Jade as we continue to progress our locally administered, sustained-release drug products designed to treat significant ocular disorders such as corneal defects and ulcers. He is well known and respected both in the Salt Lake City area and nationally for his entrepreneurial and company-building achievements, and he has served on the Boards of numerous start-up life sciences companies."

Said Dr. Patel: "Jade represents an attractive combination of proprietary, lower-risk products addressing unmet needs in potentially blinding ophthalmic conditions. I look forward to working with the Company's Board and management team to help bring these products to the patients who need them."

About Jade Therapeutics

Jade Therapeutics, founded by Drs. Barbara Wirostko and MaryJane Rafii, is a privately held company headquartered in Salt Lake City, Utah, that develops locally administered, sustained-release formulations of (mostly) already-approved drugs for use in poorly served ophthalmic indications. This approach could enable improved therapeutic outcomes along with increased patient compliance to therapy, decreased frequency of administration and office visits, and avoidance of subsequent surgeries – ultimately resulting in better visual function with enhanced quality of life.  Jade believes that its use of proprietary administration formulations of drugs that have already received regulatory approval may significantly decrease development risks and shorten the clinical trial and regulatory approval process. Jade's lead programs focus on delivering (1) recombinant human growth hormone to help address persistent corneal epithelial defects, and (2) antibiotics to treat bacterial keratitis and corneal ulcers (utilizing funding from a recently awarded National Science Foundation SBIR grant). For additional information about Jade, please visit www.jadetherapeutics.com

Contact:
Arthur Klausner
Jade Therapeutics, Inc.
646-918-7479
Email

 

Read more news from Jade Therapeutics.

 


'/>"/>
SOURCE Jade Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
2. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
3. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
4. Convoy Therapeutics Appoints Clinical Advisory Board
5. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
6. United Therapeutics Corporation Reports Third Quarter 2013 Financial Results
7. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
8. Moderna Therapeutics Named to the World Economic Forums Community of "Global Growth Companies"
9. United Therapeutics Corporation to Announce Third Quarter 2013 Financial Results Before Market Open on Tuesday, October 29, 2013
10. PTC Therapeutics Expands Management Team
11. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... , ... October 09, 2017 , ... At its national ... Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been ... a member of the winning team for the 2015 Breakthrough Prize in Fundamental physics ...
(Date:10/9/2017)... (PRWEB) , ... October 09, ... ... published on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s ... the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using ...
(Date:10/7/2017)... ... October 06, 2017 , ... Phase ... metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers can ... Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ProxiMeta ...
(Date:10/6/2017)... ... October 06, 2017 , ... The ... and technology sector at their fourth annual Conference where founders, investors, innovative practitioners ... and the ELEVATE pitch competition showcasing early stage digital health and med tech ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):